Quadrant Capital Group LLC Sells 237 Shares of Fresenius Medical Care Corporation (FMS)

Quadrant Capital Group LLC decreased its holdings in Fresenius Medical Care Corporation (NYSE:FMS) by 6.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,499 shares of the company’s stock after selling 237 shares during the quarter. Quadrant Capital Group LLC’s holdings in Fresenius Medical Care Corporation were worth $158,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of FMS. UBS Asset Management Americas Inc. boosted its stake in shares of Fresenius Medical Care Corporation by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after purchasing an additional 81 shares during the period. Pacer Advisors Inc. purchased a new position in shares of Fresenius Medical Care Corporation in the second quarter valued at approximately $179,000. FFT Wealth Management LLC purchased a new position in shares of Fresenius Medical Care Corporation in the second quarter valued at approximately $201,000. RMB Capital Management LLC purchased a new position in shares of Fresenius Medical Care Corporation in the first quarter valued at approximately $220,000. Finally, HPM Partners LLC purchased a new position in shares of Fresenius Medical Care Corporation in the second quarter valued at approximately $221,000. 2.61% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Quadrant Capital Group LLC Sells 237 Shares of Fresenius Medical Care Corporation (FMS)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/10/11/quadrant-capital-group-llc-sells-237-shares-of-fresenius-medical-care-corporation-fms.html.

Several research firms have recently commented on FMS. Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “sell” rating to a “hold” rating in a research note on Monday. Royal Bank Of Canada reissued a “hold” rating and issued a $44.00 price objective on shares of Fresenius Medical Care Corporation in a research note on Wednesday, September 13th. DZ Bank AG reissued a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Monday, August 7th. BidaskClub lowered shares of Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, UBS AG reissued a “sell” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. Fresenius Medical Care Corporation has an average rating of “Hold” and a consensus price target of $48.67.

Fresenius Medical Care Corporation (NYSE:FMS) traded up 1.17% on Wednesday, hitting $48.30. 40,118 shares of the stock traded hands. The firm’s 50-day moving average price is $48.13 and its 200-day moving average price is $46.74. Fresenius Medical Care Corporation has a 12-month low of $38.05 and a 12-month high of $50.22. The stock has a market cap of $29.75 billion, a price-to-earnings ratio of 23.79 and a beta of 0.48.

Fresenius Medical Care Corporation (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by ($0.05). The company had revenue of $4.47 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.96 EPS. On average, equities research analysts anticipate that Fresenius Medical Care Corporation will post $2.34 EPS for the current fiscal year.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply